Gynecologic Oncology xxx (xxxx) xxx

Contents lists available at ScienceDirect

Gynecologic Oncology

journal homepage: www.elsevier.com/locate/ygyno

Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer

Giorgio Bogani [a,*,1], Violante Di Donato [a,1], Giovanni Scambia [b], Fabio Landoni [c], Fabio Ghezzi [d], Ludovico Muzii [a], Pierluigi Benedetti Panici [a], Francesco Raspagliesi [e], The investigator of the Italian Gynecological Cancer Study Group [2]

[a] Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy
[b] Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
[c] Department of Obstetrics and Gynaecology, San Gerardo Hospital, Monza, Italy
[d] Department of Obstetrics and Gynaecology, University of Insubria, F. Del Ponte Hospital, Varese, Italy
[e] Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

HIGHLIGHTS

- The publication of the LACC trial determined a shift from the use of minimally invasive to open surgery.
- Overall and severe 90-day complication rates were not influenced by the surgical approach.
- The paradigm shift from minimally invasive to open radical hysterectomy does not increase the complication rate.

ARTICLE INFO

Article history:
Received 29 June 2022
Received in revised form 17 July 2022
Accepted 19 July 2022
Available online xxxx

Keywords:
Laparoscopy
Radical hysterectomy
Morbidity
Complications

ABSTRACT

Background. To evaluate the impact of the Laparoscopic Approach to Cervical Cancer (LACC) Trial on patterns of care and surgery-related morbidity in early-stage cervical cancer.

Methods. This is a retrospective, a multi-institutional study evaluating 90-day surgery-related outcomes of patients undergoing treatment for early-stage cervical cancer before (period I: 01/01/2016–06/01/2018) and after (period II: 01/01/2019–06/01/2021) the publication of the results of the LACC trial.

Results. Charts of 1295 patients were evaluated: 581 (44.9%) and 714 (55.1%) before and after the publication of the LACC trial, respectively. After the publication of the LACC trial, the number of patients treated with minimally invasive radical hysterectomy decreased from 64.9% to 30.4% ($p < 0.001$). Overall, 90-day complications occurred in 110 (18.9%) and 119 (16.6%) patients in the period I and period II, respectively ($p = 0.795$). Similarly, the number of severe (grade 3 or worse) complications did not differ between the two periods (38 (6.5%) vs. 37 (5.1%); $p = 0.297$). Overall and severe 90-day complications were consistent between periods even evaluating stage IA ($p = 0.471$), IB1 ($p = 0.929$), and IB2 ($p = 0.074$), separately.

Conclusions. The present investigation highlighted that in referral centers the shift from minimally invasive to open radical hysterectomy does not influence 90-day surgery-related morbidity.

1. Introduction

Over recent years, the minimally invasive approach has revolutionized surgical care [1]. Accumulating evidence highlighted that minimally invasive surgery correlated with better perioperative outcomes than open surgery [2,3]. In comparison to open surgery, minimally-invasive surgery is associated with lower postoperative pain, recovery time, hospital stays, and marked improvements in cosmetic outcome and overall cost-effectiveness either in benign or malignant disease. Level A evidence supports the adoption of

* Corresponding author at: Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, Viale del Policlinico 155, Rome, Italy.
E-mail address: giorgiobogani@yahoo.it (G. Bogani).
[1] Co-first author.
[2] See members of The investigator of the Italian Gynecological Cancer Study Group in Appendix B.

https://doi.org/10.1016/j.ygyno.2022.07.022
0090-8258/

minimally invasive surgery in endometrial cancer [2]. Minimally invasive approach correlates with improved short-term postoperative course and morbidity than open surgery without affecting oncologic outcomes. Similarly, retrospective data highlighted the feasibility of laparoscopic radical hysterectomy in patients with early-stage cervical cancer [4–6].

The Laparoscopic Approach to Cervical Cancer (LACC) Trial was designed to assess the non-inferiority of a minimally invasive approach in comparison to open surgery [7]. However, the unexpected results of the LACC trial showed that a minimally invasive approach is associated with lower rates of disease-free survival and overall survival than open abdominal radical hysterectomy among women with early-stage cervical cancer [7]. Moreover, two secondary analyses of the randomized LACC trial suggested that minimally invasive and open approaches correlated with similar morbidity rates and postoperative quality of life (QoL) [8,9]. The publication of the LACC trial impacted clinical practice, dramatically. We assisted in a rapid paradigm shift, with a decrease in the adoption of minimally invasive radical hysterectomy [10,11]. Lewicki PJ et al., assessed the use of minimally invasive surgery as compared with open radical hysterectomy for cervical cancer before and after the publication of the LACC Trial. Using data from the Premier Healthcare Database, the authors highlighted that the minimally invasive approach decreased from 58.0% (pre-LACC) to. 42.9% (post-LACC) [10]. Other studies reported similar findings [11]. Interestingly, they observed that the increased adoption of open radical hysterectomy resulted in an increased surgery-related morbidity rate. In order to assess patterns of utilization of minimally invasive and open radical hysterectomy as well as surgery-related morbidity, we designed the present investigation.

2. Methods

This is a multi-institutional retrospective study coordinated by the Fondazione IRCCS Istituto Nazionale dei Tumori. As coordinator center the Institutional Review Board of the Fondazione IRCCS Istituto Nazionale dei Tumori approved this investigation (#572020). Charts of patients affected by early-stage cervical cancer (stage IA- IB2) were collected in 24 referral centers in Italy. The primary endpoint measure was to evaluate how the publication of the LACC trial impacted patterns of care and surgery-related morbidity of patients affected by early-stage cervical cancer. For the purpose present study, we collected medical records of consecutive patients with newly diagnosed early-stage cervical cancer treated in Italy before (period I: 01/01/2016–06/01/2018) and after (period II: 01/01/2019–06/01/2021) the publication of the results of the LACC trial [7]. Supplemental material 1 displays the centers participating in the study.

We included consecutive patients receiving treatment (i.e., conservative approach, radical hysterectomy, and radiotherapy) in period I and period II. We included patients aged ≥18 years old, with a confirmed histological diagnosis of early-stage cervical cancer. In all included centers, data concerning surgical procedures, peri-operative details, as well as 90-day follow-up evaluations were recorded in computerized databases, updated by trained residents and nurses on a regular basis.

Exclusion criteria were: (i) stage II endometrial cancer receiving radical hysterectomy; (ii) administration of neoadjuvant chemotherapy; (iii) lack of data of 90-day postoperative course; (iv) consent withdrawal. During the two study periods, there were no significant differences in the facilities available for patient care and in the referral patterns of our services. Other features of patient management remained consistent in the two periods. The TNM classification was applied in order to categorize patients *per* stage [12]. Postoperative complications included any deviation of normal postoperative course, within 90 days. To improve quality of complication reporting complications were graded per a severity system [13,14]. The Clavien-Dindo classification was adopted to grade postoperative complications [13]. For the purpose of this study only severe complications, occurring within 90-day, are reported. They included events requiring surgical, endoscopic, or radiological intervention (with or without general anesthesia). Additionally, life threatening complications (including intensive care unit (ICU) admission as well as single or multi organ dysfunction) and postoperative death are registered [13]. Martin criteria were applied to improve quality of complications reporting [14]. Intraoperative complications were abstracted as well.

2.1. Statistical methods

Basic descriptive statistics were used to describe the study populations. Differences in categorical variables were analyzed using the Fisher exact and Chi-square test when comparing two and three (or more) groups, respectively. When indicated odds ratio (OR) and 95% confidence intervals (95%CI) were calculated. *t*-test and Mann-Whitney tests were used to compare continuous variables as appropriate. *P* values <0.05 were considered statistically significant. Statistical analysis was performed with GraphPad Prism version 6.0 (GraphPad Software, San Diego CA) and IBM-Microsoft SPSS version 20.0 (SPSS Statistics. International Business Machines Corporation IBM 2013 Armonk, USA) for Mac.

3. Results

Charts of 1327 patients were retrieved. Data of 32 patients were excluded since they did not match the inclusion criteria. The study included 1295 patients: 581 (44.9%) and 714 (55.1%) before and after the publication of the LACC trial, respectively. The study population included 199 (34.2%), 211 (36.3%), and 171 (29.4%) patients with stage IA, stage IB1, and stage IB2 treated in the period I and 293 (41.1%), 219 (30.6%), and 202 (28.3%) patients with stage IA, stage IB1, and stage IB2 treated in the period II ($p = 0.028$; p-for trend <0.001). The proportion of patients receiving conservative treatments increase over the study period (13.6% vs. 20.6%; p-for trend <0.001); while the proportion of patients receiving radiotherapy (with or without chemotherapy) remained stable in the two periods (5.8% vs. 7.3%; $p = 0.303$). Fig. 1 shows the flow of patients through the study design. Table 1 reports data of patients treated in the period I and period II. Data for patients affected by stage IA, IB1, and IB2 are reported in Supplemental material 2, 3, and 4, respectively. After the publication of the LACC trial, the number of patients treated with minimally-invasive radical hysterectomy decreased from 64.9% (304 out of 468 radical hysterectomies) to 30.4%



Fig. 1. Study design.

Table 1
Patterns of care before and after the publication of the LACC trial.

	Period I (01/2016–06/2018)	Period II (01/2019–6/2021)	P value
	$N = 581$	$N = 714$	
Stage of disease*			0.028
Stage IA	199 (34.2%)	293 (41.1%)	
Stage IB1	211 (36.3%)	219 (30.6%)	
Stage IB2	171 (29.4%)	202 (28.3%)	
Conservative treatments**	79 (13.6%)	147 (20.6%)	<0.001
Minimally invasive radical hysterectomy plus nodal dissection	304 (52.3%)	157 (21.9%)	<0.001
Laparoscopic radical hysterectomy plus SNM	47 (8.1%)	65 (9.1%)	0.518
Laparoscopic radical hysterectomy plus lymphadenectomy	171 (29.4%)	55 (7.7%)	<0.001
Robotic-assisted radical hysterectomy plus SNM	15 (2.6%)	17 (2.4%)	0.816
Robotic-assisted radical hysterectomy plus lymphadenectomy	71 (12.2%)	20 (2.8%)	<0.001
Open radical hysterectomy plus nodal dissection	164 (28.2%)	358 (50.1%)	<0.001
Open radical hysterectomy plus SNM	6 (1%)	68 (9.5%)	<0.001
Open radical hysterectomy plus lymphadenectomy	158 (27.2%)	290 (40.6%)	<0.001
Radiotherapy (with or without chemotherapy)	34 (5.8%)	52 (7.3%)	0.303

Abbreviation: SNM, sentinel node mapping.
* Stage of disease according to the TNM classification system.
** Conservative treatments included any treatment performed via vaginal route (e.g., conization and trachelectomy) with or without nodal dissection (any surgical route).

(157 out of 515 radical hysterectomies) ($p < 0.001$).The decrease of minimally-invasive radical hysterectomy rates was observed for patients with stage IA (81.8% vs. 58.2% (−23.6%); $p < 0.001$), stage IB1 (68.8% vs. 20.3% (−48.5%); $p < 0.001$), and stage IB2 (45.3% vs. 14.5% (−30.8%); $p < 0.001$). All participating centers suggested that they adopted protective maneuvers with the aim to reduce the risk of disease dissemination at the time of minimally invasive radical hysterectomy. Those maneuvers included: (i) preoperative tumor removal thorough conization ($n = 130$), the avoidance of the use of uterine manipulator ($n = 87$), vaginal closure before colpotomy ($n = 37$). In most cases, surgeons adopted more than one technique to reduce possible contamination of the abdominal cavity. These maneuvers were used in 86% of patients with tumors <2 cm and 100% of tumors larger than 2 cm. Intraoperative complication rates were similar between period I and period II (2.4% vs. 1.4%; $p = 0.215$). Overall, 90-day complications occurred in 110 (18.9%) and 119 (16.6%) patients in the period I and period II, respectively ($p = 0.795$). Similarly, the number of severe (grade 3 or worse) complications were not influenced by the publication of the LACC trial (38 (6.5%) vs. 37 (5.1%); $p = 0.297$). Overall and severe 90-day complications were consistent between periods even evaluating stage IA, IB1, and IB2, separately ($p > 0.20$). Table 2 shows overall and severe complications that occurred in period I and period II.

Considering available data on perioperative data, we observed that minimally invasive radical hysterectomy correlated with similar operative time (235 vs. 244 min; $p = 0.261$) and lower blood loss (100 vs. 200; $p < 0.001$) in comparison to open surgery. The mean (SD) postoperative recovery time was 2 (1.1) and 4 (2.4) days after minimally-invasive and open radical hysterectomy ($p < 0.001$).

4. Discussion

The present study evaluated changes in patterns of care and treatment-related morbidity in early-stage cervical cancer patients after the publication of the LACC trial [7]. The present study reported a number of noteworthy findings. First, we observed that the prevalence of minimally invasive radical hysterectomy significantly decreased after the publication of the LACC trial [7]. Second, the burden of intraoperative, 90-day postoperative complications, and 90-day severe postoperative complications remained stable over the periods. This finding was confirmed after stratification per stage of the disease. Third, we assisted an increased number of patients undergoing treatments in period II.

The LACC trial was designed to test the non-inferiority of minimally invasive radical hysterectomy in comparison to open radical hysterectomy in early-stage cervical cancer [7]. The trial planned to enroll 740 patients. However, the trial was suspended earlier (after the enrollment of 631 patients) since the imbalance in deaths between the two groups [7]. Ramirez et al., observed that patients undergoing minimally invasive radical hysterectomy had lower disease-free (91.2% vs. 97.1%) and overall (93.8% vs. 99%) survival rates and a higher rate of locoregional recurrence (94.3% vs. 98.3%) than patients who underwent open abdominal radical hysterectomy [7]. These findings were corroborated by an epidemiological study published in the same issue of the NEJM [15]. Melamed et al., reported data of patients with early-stage cervical cancer treated during the 2010–2013 period at Commission on Cancer-accredited hospitals in the United States. They also conducted an interrupted time-series analysis involving patients undergoing radical hysterectomy during the 2000–2010 period, using the Surveillance,

Table 2
90-day postoperative complications.

	Period I (01/2016–06/2018)	Period II (01/2019–6/2021)	P value
All population	581	714	
90-day postoperative complications	110 (18.9%)	119 (16.6%)	0.795
90-day postoperative severe complications*	38 (6.5%)	37 (5.1%)	0.297
Stage IA	199	293	
90-day postoperative complications	14 (7%)	22 (7.5%)	0.843
90-day postoperative severe complications*	4 (2%)	9 (1.2%)	0.471
Stage IB1	211	219	
90-day postoperative complications	44 (20.8%)	49 (22.3%)	0.701
90-day postoperative severe complications*	14 (6.6%)	15 (6.8%)	0.929
Stage IB2	171	202	
90-day postoperative complications	52 (30.4%)	48 (23.7%)	0.148
90-day postoperative severe complications*	20 (11.7%)	13 (6.4%)	0.074

Complications were graded per the Clavien-Dindo classification system [13].

Epidemiology, and End Results (SEER) program database [15]. In this paper, the authors observed that after a median follow-up of 45 months, the mortality rate was 9.1% and 5.3% after minimally invasive and open radical hysterectomy, respectively [15]. After the publication of those two studies, accumulating evidence suggested the detrimental role of minimally invasive radical hysterectomy [16,17]. Reasons, why the execution of minimally invasive hysterectomy correlates with poor outcomes, are still unknown. The most imputable reasons are the possible contamination of the pelvic cavity at the time of colpotomy and the flow of CO2 that might spread the cells into the abdominal cavity [16,18]. We must note that the CO2 pressure might cause the penetration of the cells into the superficial mesothelial layer of the peritoneum. Moreover, the CO2 might promote the spread of the cells in mechanical and biochemical ways. Interestingly, research from our study group evaluated patterns of recurrence in patients undergoing laparoscopic and open radical hysterectomy [19]. Applying a propensity-matched comparison, the findings of this study highlighted that patients undergoing laparoscopic radical hysterectomy are at higher risk of developing intrapelvic recurrences and peritoneal carcinomatosis in comparison to patients undergoing open radical hysterectomy [19]. We assisted in a paradigm shift from minimally invasive to open radical hysterectomy [20].

The LACC trial is one of the most impacting studies in the field of gynecologic oncology, being a game-changer. Even the NEJM classified the LACC trial as one of the most impacting studies for the year 2018 [7]. Accumulating data from the U.S. suggested that after the publication of the LACC trial, a dramatic decrease in the adoption of minimally invasive radical hysterectomy was observed [10,11]. Interestingly, Matsuo K et al., evaluating the National Inpatient Sample from October 2015 to December 2018, evaluated data of 5120 and 1645 patients undergoing surgery before and after the publication of the LACC. In the post LACC period patients were less likely to have a minimally invasive radical hysterectomy (−63%), but more likely to develop perioperative complications (+23%) and longer length of hospital stay (3 vs. 2 days) [11]. The present study provides similar findings, we observed an important (statistically significant) decrease in the adoption of minimally invasive radical hysterectomy that was more evident in patients with stage IB1 (−48.5%), than for stage IB2 (−30.8%), and stage IA (−23.6%). However, we have to highlight that the reduction of minimally invasive radical hysterectomy rates was less pronounced than those expected. In our series, the shift from minimally invasive to open hysterectomy did not correlate with an increased morbidity rate. This data corroborated the secondary analysis of the LACC trial suggesting that surgery-related morbidity does not differ significantly between the two approaches [8]. The inherent biases related to the retrospective nature of the study design are the main weaknesses of the present paper. Additionally, four points of the present paper have to be addressed: (i) due to the absence of follow-up, we are not able to evaluate the impact of this paradigm shift on oncologic outcomes of early-stage cervical cancer patients involved in this study. (ii) we observed an increased number of patients treated in period II; this feature might be related both to the improvement in patients' workflow and due to COVID-19. After the onset of the COVID-19 outbreak, we assisted to centralization of oncologic cases in referral - highly specialized centers (like those included in our series) [21]. (iii) We collected a huge amount of data (more than 1300 patients) from the whole Italian territory, with a potential missing of cervical cancer cases diagnosed and treated in low volume centers. (iv) We were not able to correct our results on the basis of patients demographic characteristics. The main merit of the present study is the inclusion of a large sample size of consecutive patients treated before and after the publication of the LACC trial [7]. Moreover, this paper investigated the impact of the LACC trial in a European country for the first time. Interestingly, the inclusion of patients who had not radical surgery (i.e., conservative treatment and radiotherapy) would help to avoid possible allocation biases and to better understand the changes in patterns of care in cervical cancer management.

In conclusion, the present study evaluated changes in the pattern of care in patients treated before and after the publication of the LACC trial [7]. We assisted in an important decrease in minimally invasive radical hysterectomy, over time. The increased prevalence of open surgery did not correlate with worse perioperative outcomes. Intraoperative, postoperative, and severe postoperative complication rates were similar between groups. Further evidence is warranted to assess peri-operative and long-term changes in early-stage cervical cancer, provided by the LACC trial [7].

Credit authorship contribution statement

Giorgio Bogani: Conceptualization, Methodology, Project administration, Data curation, Supervision, Validation, Writing - original draft, Writing - review & editing. **Violante Di Donato:** Conceptualization, Methodology, Project administration, Data curation, Formal analysis, Validation, Visualization, Writing - original draft, Writing - review & editing. **Giovanni Scambia:** Conceptualization, Methodology, Supervision, Data curation, Formal analysis, Project administration, Visualization, Writing - original draft, Writing - review & editing. **Fabio Landoni:** Conceptualization, Methodology, Data curation, Formal analysis, Supervision, Validation, Visualization, Writing - original draft, Writing - review & editing. **Fabio Ghezzi:** Conceptualization, Methodology, Data curation, Formal analysis, Supervision, Validation, Visualization, Writing - original draft, Writing - review & editing. **Ludovico Muzii:** Conceptualization, Methodology, Data curation, Formal analysis, Supervision, Validation, Writing - original draft, Writing - review & editing. **Pierluigi Benedetti Panici:** Conceptualization, Methodology, Investigation, Supervision, Validation, Visualization, Writing - original draft, Writing - review & editing. **Francesco Raspagliesi:** Conceptualization, Methodology, Supervision, Data curation, Formal analysis, Investigation, Project administration, Validation, Visualization, Writing - original draft, Writing - review & editing.

Declaration of Competing Interest

The Authors declare no conflicts of interest.

No funding sources supported this investigation.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ygyno.2022.07.022.

Appendix B

Giorgio Bogani[1], Violante Di Donato[1], Giovanni Scambia[2], Fabio Ghezzi[3], Jvan Casarin[3], Fabio Landoni[4,5], Giampaolo Di Martino[4], Tommaso Grassi[4], Anna Myriam Perrone[6], Pierandrea De Iaco[6], Francesco Multinu[7], Roberto Berretta[8], Vito A. Capozzi[8], Errico Zupi[9], Gabriele Centini[9], Antonio Pellegrino[10], Silvia Corso[10], Guido Stevenazzi[11], Anna Chiara Boschi[12], Giuseppe Comerci[12], Pantaleo Greco[13], Gennaro Scutiero[13], Francesco Sopracordevole[14], Giorgio Giorda[14], Mariasole Fichera[14], Tommaso Simoncini[15], Marta Caretto[15], Enrico Sartori[16], Federico Ferrari[16], Antonio Cianci[17], Giuseppe Sarpietro[17], Maria Grazia Matarazzo[17], Pierluigi Giampaolino[18], Giuseppe Bifulco[18], Michele Morelli[19], Michele Di Dio[19], Annamaria Ferrero[20], Nicoletta Biglia[20], Fabio Barra[21], Simone Ferrero[21], Stefano Cianci[22], Vito Chiantera[23], Giulio Sozzi[23], Alfredo Ercoli[22], Sergio Schettini[24], Teresa Orlando[24], Francesco G. Cannone[25], Giuseppe Ettore[25], Andrea Puppo[26], Elena Olearo[26], Umberto Leone Roberti Maggiore[27], Valeria Artuso[27], Innocenza Palaia[1], Giorgia Perniola[1], Rossana Tripodi[1]D'AugeTullio Golia D'Augè[1], Ilaria Cuccu[1], Margherita Fischetti[1], Giusi Santangelo[1], Assunta Casorelli[1], Andrea Giannini[1], Ottavia D'Oria[1], Giuseppe Vizzielli[28], Stefano Restaino[28], Alice Bergamini[29], Luca Bocciolone[29], Francesco Plotti[30], Roberto Angioli[30], Giulia Mantovani[31], Marcello Ceccaroni[31], Chiara Cassini[32], Mattia Dominoni[32], Laura Giambanco[33,57], Silvia Amodeo[33,57], Livio Leo[34],

Raphaël Thommaset[34], Diego Raimondo[35], Renato Seracchioli[35], Mario Malzoni[36], Francesca Falcone[36], Franco Gorlero[37], Martina Di Luca[37], Enrico Busato[38], Sami Kilzie[38], Andrea Dell'Acqua[39], Giovanna Scarfone[39], Paolo Vercellini[39], Marco Petrillo[40], Giampiero Capobianco[40], Andrea Ciavattini[41], Liliana Mereu[42], Paolo Scollo[42], Flavia Sorbi[43], Massimiliano Fambrini[43], Federico Romano[44], Giuseppe Ricci[44,45], Giuseppe Trojano[46], Gianluca Raffaello Damiani[46], Roberto Consonni[47], Nadia Di Lorenzo[47], Antonio Lippolis[48], Raffaele Tinelli[48], Lorenzo Aguzzoli[49], Vincenzo D. Mandato[49], Stefano Palomba[50], Marcello Tripodi[50], Davide Calandra[51], Franco Pellegrini[51,52], Fulvio Zullo[53], Daniela Surico[54], Valentino Remorgida[54], Francesco Ruscitto[55], Paolo Beretta[55], Enrico Vizza[56], Ludovico Muzii[1], Pierluigi Benedetti Panici[1], Francesco Raspagliesi[27]

[1] *Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy*
[2] *Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy*
[3] *Department of Obstetrics and Gynaecology, University of Insubria, F. Del Ponte Hospital, Varese, Italy*
[4] *Department of Obstetrics and Gynaecology, San Gerardo Hospital, Monza, Italy*
[5] *University Milano - Bicocca, Milano, Italy*
[6] *Unit of Gynecology, AOU S. Orsola – Malpighi, Bologna, Italy*
[7] *Department of Gynecologic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy*
[8] *Department of Obstetrics and Gynaecology, University of Parma, Parma, Italy*
[9] *Department of Obstetrics and Gynaecology, University of Siena, Siena, Italy*
[10] *Department of Obstetrics and Gynaecology, ASST Lecco – Ospedale Alessandro Manzoni, Lecco, Italy*
[11] *Department of Obstetrics and Gynaecology, ASST OVEST MI, Legnano (Milan) Hospital, Legnano, Italy*
[12] *Department of Obstetrics and Gynaecology, AUSL Romagna, Ospedale "Santa Maria delle Croci", Ravenna, Italy*
[13] *Clinica Ostetrica e Ginecologica, Dipartimento Scienze Mediche, Università di Ferrara, Ferarra, Italy*
[14] *Gynecological Oncology Unit, Centro di Riferimento Oncologico - National Cancer Institute, Aviano, Italy*
[15] *Department of Clinical and Experimental Medicine, Division of Obstetrics and Gynecology, University of Pisa, Pisa, Italy*
[16] *Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy*
[17] *Department of General Surgery and Medical-Surgical Specialties, Gynecological Clinic, University of Catania, Catania, Italy*
[18] *Department of Obstetrics and Gynaecology, AOU Federico II, Naples, Italy*
[19] *Department of Obstetrics and Gynaecology, AO "S.S. Annunziata", Cosenza, Italy*
[20] *Academic Department of Obstetrics and Gynecology, Mauriziano Hospital, Torino, Italy*
[21] *Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genova, Italy*
[22] *Department of Human Pathology of Adult and Childhood "G. Barresi", Unit of Gynecology and Obstetrics University of Messina, Italy*
[23] *Department of Gynecologic Oncology, University of Palermo, Italy*
[24] *Department of Obstetrics and Gynaecology, AOR San Carlo, Potenza, Italy*
[25] *Department of Obstetrics and Gynaecology, ARNAS Garibaldi Catania, Catania, Italy*
[26] *Department of Obstetrics and Gynaecology, ASO Santa Croce e Carle, Cuneo, Italy*
[27] *Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy*
[28] *Department of Maternal and Child Health, University-Hospital of Udine, Udine, Italy*
[29] *Department of Obstetrics and Gynaecology, IRCCS San Raffaele Hospital, Milan, Italy*
[30] *Department of Obstetrics and Gynecology, Campus Bio-Medico University of Rome, Rome, Italy*
[31] *Department of Obstetrics and Gynecology, Gynecology Oncology and Minimally-Invasive Pelvic Surgery, International School of Surgical Anatomy, Sacred Heart Hospital Negrar, Verona, Italy*
[32] *Department of Obstetrics and Gynecology, IRCCS Foundation Policlinico San Matteo and University of Pavia, Pavia, Italy*
[33] *Department of Obstetrics and Gynecology, S. Antonio Abate Hospital, Trapani, Italy*
[34] *Departments of Gynecology & Obstetrics- Hopital Beauregard- AUSL Valleè d'Aoste, Aosta, Italy*
[35] *Division of Gynaecology and Human Reproduction Physiopathology, Department of Medical and Surgical Sciences (DIMEC), IRCCS Azienda Ospedaliero-Univeristaria di Bologna. S. Orsola Hospital, University of Bologna, Bologna, Italy*
[36] *Endoscopica Malzoni, Center for Advanced Endoscopic Gynecologic Surgery, Avellino, Italy*
[37] *Department of Obstetrics and Gynaecology, Ente Ospedaliero Ospedali Galliera, Genova, Italy*
[38] *Department of Obstetrics and Gynaecology, Ospedale di Treviso, Treviso, Italy*
[39] *Gynaecology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy*
[40] *Gynecologic and Obstetric Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy*
[41] *Gynecologic Section, Department of Odontostomatologic and Specialized Clinical Sciences, Università Politecnica delle Marche, Ancona, Italy*
[42] *Department of Obstetrics and Gynecology, Oncological Gynecology Unit, Ospedale Cannizaro, Catania, Italy*
[43] *Gynecology Unit, Careggi University Hospital, Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy*
[44] *Department of Obstetrics and Gynaecology, Institute for Maternal and Child Health, IRCCS 'Burlo Garofolo', Trieste, Italy*
[45] *Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy*
[46] *Department of Obstetrics and Gynaecology, Madonna delle Grazie Hospital ASM, Matera, Italy*
[47] *Gynecology Unit, Ospedale Valduce, Como, Italy*
[48] *Unit of Obstetrics and Gynaecology, Valle D'Itra Hospital, Martina Franca, Taranto, Italy*
[49] *Unit of Obstetrics and Gynecology, Azienda Unità Sanitaria Locale -IRCCS, Reggio Emilia, Italy*
[50] *Unit of Obstetrics and Gynecology, GOM of Reggio Calabria & University 'Magna Graecia' of Catanzaro, Italy*
[51] *Unit of Obstetrics and Gynecology, University G. D'Annunzio of Chieti-Pescara, Italy*
[52] *Unit of Obstetrics and Gynecology, Santo Spirito Hospital, Pescara, Italy*
[53] *Unit of Obstetrics and Gynecology, Università "Magna Graecia" di Catanzaro, Catanzaro, Italy*
[54] *Unit of Obstetrics and Gynecology, University of Eastern Piedmont, Novara, Italy*
[55] *Gynecology Unit, Ospedale Valduce, Como– ASST Lariana, S. Anna, Como, Italy*
[56] *Gynecologic Oncology Unit, Department of Experimental Clinical Oncology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy*
[57] *Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy*

References

[1] M.S. Orlando, C.C. Greenberg, S.R. Pavuluri Quamme, A. Yee, A.E. Faerber, C.R. King, Surgical coaching in Obstetrics and Gynecology: an evidence-based strategy to elevate surgical education and promote lifelong learning, Am J Obstet Gynecol. (2022) https://doi.org/10.1016/j.ajog.2022.02.006 (Epub ahead of print. PMID: 35176285).
[2] J.L. Walker, M.R. Piedmonte, N.M. Spirtos, S.M. Eisenkop, J.B. Schlaerth, R.S. Mannel, et al., Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study, J Clin Oncol. 30 (7) (2012) 695–700, https://doi.org/10.1200/JCO.2011.38.8645 (Epub 2012 Jan 30. Erratum in: J Clin Oncol. 2012 May 1; 30(13):1570. PMID: 22291074; PMCID: PMC3295548).
[3] S. Yin, W. Gao, P. Shi, M. Xi, W. Tang, J. Zhang, Primary laparoscopic surgery does not affect the prognosis of early-stage ovarian clear cell cancer, Cancer Manag. Res. 14 (13) (2021) 6403–6409, https://doi.org/10.2147/CMAR.S321173 (PMID: 34421313; PMCID: PMC8372305).
[4] X. Hao, S. Han, Y. Wang, Comparison of conventional laparoscopy and robotic radical hysterectomy for early-stage cervical cancer: a meta-analysis, J. Cancer Res. Ther. (Suppl) (2015) C258–C264, https://doi.org/10.4103/0973-1482.170533 (PMID: 26612449).
[5] Y.Z. Wang, L. Deng, H.C. Xu, Y. Zhang, Z.Q. Liang, Laparoscopy versus laparotomy for the management of early stage cervical cancer, BMC Cancer 24 (15) (2015) 928, https://doi.org/10.1186/s12885-015-1818-4 (PMID: 26596955; PMCID: PMC4657298).
[6] J. Cai, L. Yang, W. Dong, H. Wang, Z. Xiong, Z. Wang, Retrospective comparison of laparoscopic versus open radical hysterectomy after neoadjuvant chemotherapy for locally advanced cervical cancer, Int. J. Gynaecol. Obstet. 132 (1) (2016) 29–33, https://doi.org/10.1016/j.ijgo.2015.06.042 (Epub 2015 Sep 25. PMID: 26434669).
[7] P.T. Ramirez, M. Frumovitz, R. Pareja, A. Lopez, M. Vieira, R. Ribeiro, et al., Minimally invasive versus abdominal radical hysterectomy for cervical cancer, N. Engl. J. Med. 379 (20) (2018) 1895–1904, https://doi.org/10.1056/NEJMoa1806395 (Epub 2018 Oct 31. PMID: 30380365).
[8] A. Obermair, R. Asher, R. Pareja, M. Frumovitz, A. Lopez, R. Moretti-Marques, et al., Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial, Am J Obstet Gynecol. 222 (3) (2020) 249.e1–249.e10, https://doi.org/10.1016/j.ajog.2019.09.036 (Epub 2019 Oct 3. Erratum in: Am J Obstet Gynecol. 2020 Nov;223(5):757. PMID: 31586602; PMCID: PMC7181470).
[9] M. Frumovitz, A. Obermair, R.L. Coleman, R. Pareja, A. Lopez, R. Ribero, et al., Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial, Lancet Oncol. 21 (6) (2020) 851–860, https://doi.org/10.1016/S1470-2045(20)30081-4 (Erratum in: Lancet Oncol. 2020 Jul;21 (7):e341. PMID: 32502445).
[10] P.J. Lewicki, S.P. Basourakos, Y. Qiu, J.C. Hu, D. Sheyn, A. Hijaz, et al., Effect of a randomized, controlled trial on surgery for cervical cancer, N. Engl. J. Med. 384 (17) (2021) 1669–1671, https://doi.org/10.1056/NEJMc2035819 (PMID: 33913646).
[11] K. Matsuo, R.S. Mandelbaum, M. Klar, K.M. Ciesielski, K. Matsushima, S. Matsuzaki, et al., Decreasing utilization of minimally invasive hysterectomy for cervical cancer in the United States, Gynecol. Oncol. 162 (1) (2021) 43–49, https://doi.org/10.1016/j.ygyno.2021.05.005 (Epub 2021 May 13. PMID: 33992450).
[12] N. Bhatla, J.S. Berek, M. Cuello Fredes, L.A. Denny, S. Grenman, K. Karunaratne, et al., Revised FIGO staging for carcinoma of the cervix uteri, Int J Gynaecol Obstet. 145 (1) (2022) 129–135, https://doi.org/10.1002/ijgo.12749 (Epub 2019 Jan 17. Erratum in: Int J Gynaecol Obstet. 2019 Nov;147(2):279–280. PMID: 30656645).

[13] P.A. Clavien, J. Barkun, M.L. de Oliveira, J.N. Vauthey, D. Dindo, R.D. Schulick, et al., The Clavien-Dindo classification of surgical complications: five-year experience, Ann. Surg. 250 (2) (2009) 187–196, https://doi.org/10.1097/SLA.0b013e3181b13ca2 (PMID: 19638912).

[14] R.C. Martin 2nd, M.F. Brennan, D.P. Jaques, Quality of complication reporting in the surgical literature, Ann. Surg. 235 (2002) 803–813.

[15] A. Melamed, D.J. Margul, L. Chen, N.L. Keating, M.G. Del Carmen, J. Yang, et al., Survival after minimally invasive radical hysterectomy for early-stage cervical cancer, N Engl J Med. 379 (20) (2018) 1905–1914, https://doi.org/10.1056/NEJMoa1804923 (Epub 2018 Oct 31. PMID: 30379613; PMCID: PMC6464372).

[16] L. Chiva, V. Zanagnolo, D. Querleu, N. Martin-Calvo, J. Arévalo-Serrano, M.E. Căpîlna, et al., SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer, Int. J. Gynecol. Cancer 30 (9) (2020) 1269–1277, https://doi.org/10.1136/ijgc-2020-001506 (Epub 2020 Aug 11. PMID: 32788262).

[17] G. Bogani, V. Di Donato, L. Muzii, J. Casarin, F. Ghezzi, M. Malzoni, et al., Assessing the role of minimally invasive radical hysterectomy for early-stage cervical cancer, Eur. J. Obstet. Gynecol. Reprod. Biol. 275 (2022) 64–69, https://doi.org/10.1016/j.ejogrb.2022.06.004 (Epub 2022 Jun 8. PMID: 35753229).

[18] E. Chacon, N. Manzour, V. Zanagnolo, D. Querleu, J.M. Núñez-Córdoba, N. Martin-Calvo, et al., SUCCOR cone study: conization before radical hysterectomy, Int J Gynecol Cancer (2022) https://doi.org/10.1136/ijgc-2021-002544 (Epub ahead of print. PMID: 35039455).

[19] G. Bogani, F. Ghezzi, L. Chiva, B. Gisone, C. Pinelli, A. Dell'Acqua, et al., Patterns of recurrence after laparoscopic versus open abdominal radical hysterectomy in patients with cervical cancer: a propensity-matched analysis, Int. J. Gynecol. Cancer 30 (7) (2020) 987–992, https://doi.org/10.1136/ijgc-2020-001381 (Epub 2020 May 23. PMID: 32448809).

[20] J. Casarin, G. Bogani, F. Multinu, A. Mariani, N.R. Abu-Rustum, F. Ghezzi, et al., Paradigm shifts in gynecologic oncology, Int. J. Gynecol. Cancer 31 (12) (2021 Dec) 1617, https://doi.org/10.1136/ijgc-2021-003108 (Epub 2021 Oct 29. PMID: 34716176).

[21] G. Bogani, G. Scambia, C. Cimmino, F. Fanfani, B. Costantini, M. Loverro, et al., Characteristics and patterns of care of endometrial cancer before and during COVID-19 pandemic, J Gynecol Oncol. 33 (1) (2022) e10, https://doi.org/10.3802/jgo.2022.33.e10 (Epub 2021 Nov 12. PMID: 34910391; PMCID: PMC8728669).